

Prasco Lab to market generics version of Colcrys in US

13 January 2015 | News | By BioSpectrum Bureau

Prasco Lab to market generics version of Colcrys in US



Singapore: US generics firm, Prasco Laboratories, has entered into alliance with US subsidiary of Japanese pharmaceutical company, Takeda, to distribute Colchicine tablets, the generic version of Colcrys (colchicine) Tablets in the US.

Colcrys tablets is indicated for the prophylaxis and treatment of acute gout flares in adults, and the treatment of familial Mediterranean fever (FMF) in adults and children age four or older. Colcrys is part of Takeda's gout treatment portfolio, and was launched commercially in the US in 2009

Colchicine tablets will be marketed under the Prasco label and will be widely available in US pharmacies beginning later this week.

"Introducing an authorized generic of Colcrys provides patients, pharmacists, and physicians with access to a therapeutically equivalent option to Colcrys Tablets for the prevention and treatment of gout flares," stated Mr. Chris Arington, chief executive officer, Prasco.